Business Wire

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

Share

Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.

Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds. The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient’s immune system to fight cancer.

“Boehringer Ingelheim is excited to extend our partnership with Dr. Kim and his outstanding team at Trutino Biosciences. Our existing collaboration has made rapid and impressive progress in a short time frame, and we expect this field to have potential combination benefits with our existing immune-targeting assets,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim. “The selective activation of specific cytokines localized in the tumor microenvironment holds enormous promise and has the potential to be a key element in fully harnessing the power of the immune system to fight cancer.”

“It's been two years since our initial strategic alliance began and we are very excited to further strengthen our partnership with Boehringer Ingelheim, a leader in cancer immunology, to advance potential cytokine therapeutic options that will transform the lives of cancer patients worldwide,” said Phillip Kim, Ph.D., MBA, Founder and CEO of Trutino Biosciences. “Boehringer Ingelheim has a deep commitment to our innovative scientific approaches and to bringing novel cancer therapies to patients. This global partnership validates the broad potential of our proprietary ‘On Demand Cytokine’ platform. As part of this expanded collaborative framework, we aim to rapidly develop a new generation of cytokine therapies as single agent and in combination with Boehringer Ingelheim's pipeline portfolio of cancer vaccines, oncolytic viruses, T cell engagers and other therapeutic modalities."

Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe. Until that time, Trutino will continue to operate as an independent company, with the existing fruitful strategic partnership and collaboration agreement between the companies continuing uninterrupted.

The transaction consideration consists of an option fee, the issuance of a convertible note and fixed purchase price terms to acquire Trutino Biosciences once pre-defined milestones are achieved. The option fee and principal amount of the convertible note funded by Boehringer Ingelheim at the signing of the option will collectively fully finance Trutino Biosciences through the next major development milestones of Trutino Biosciences.

Boehringer Ingelheim and Trutino Biosciences were introduced in 2019 during one of Boehringer Ingelheim’s “Grass Roots Innovation” events in San Diego. From there, in 2020 the companies forged a multi-target strategic partnership on conditionally masked cytokines. Boehringer Ingelheim’s Grass Roots programs provide biotech entrepreneurs mentoring and access to expertise and possible funding. To learn more, visit Grass Roots Innovation.

Please click on the link for "Notes to Editors":

https://www.boehringer-ingelheim.com/partnering/human-health-partnering/option-acquire-trutino-biosciences

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts

Boehringer Ingelheim

Reinhard Malin (CET time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel (EST time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Trutino Biosciences

Phillip Kim
+1 858-880-5501
pkim@trutinobio.com

John Zacamy
+1 212-486-2760
info@trutinobio.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services Inaugurates Engineering Design Centre in France28.6.2022 10:00:00 CEST | Press release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, inaugurated its Engineering Design Centre (EDC) in Toulouse, France, to initially cater to the new age digital requirements of the global aerospace and defence sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005829/en/ Seen in the picture during the Ribbon Cutting Ceremony (from left to right): Deepanshu Khurana, Embassy of India; Véronique Canceill, Airbus; Amit Chadha, LTTS; Patrice Vassal, Invest in Toulouse; Marie-Eve Rigollet, Airbus (Photo: Business Wire) The EDC will initially focus on developing cutting-edge solutions for the aerospace and defence industries and LTTS will work with major OEMs in the region as an engineering partner. The center will specialize in end-to-end solutions for aerospace design & manufacturing, with a workforce of LTTS engineers having proven expertise in digital e

Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record28.6.2022 09:43:00 CEST | Press release

A Turkish medical team has successfully separated conjoined twins shortly after birth by employing a range of innovative techniques, including virtual simulations and 3D modeling. Carried out at Istanbul’s Acibadem Hospital, the successful procedure set a new world record for the fastest-ever operation of its kind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005307/en/ Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record (Photo: Business Wire) “Thanks to our team of dedicated professionals, we were able to separate the twins in a well-planned surgical procedure that took about nine hours,” Prof. Mehmet Veli Karaaltin, who supervised the operation, says. He is an M.D. specialized in aesthetic, plastic and reconstructive surgery. As a result of the procedure, the twins, who were born conjoined at the breastbone but has two hearts, were both able to survive on their own. Born in Algeria, the

Denodo Recognized as an Enterprise Data Fabric Leader by Independent Analyst Firm Evaluation28.6.2022 09:00:00 CEST | Press release

Denodo, a leader in data management, today announced that Forrester Research, Inc., a leading independent technology and market research company, has positioned Denodo as a Leader in The Forrester Wave™: Enterprise Data Fabric, Q2 2022. According to the report, “Denodo is best fit for customers that are focusing on an enterprise-wide data fabric strategy to support BI, data collaboration, customer intelligence, data engineering, data science, IoT analytics, operational insights, and predictive analytics use cases.” The complete and complementary report, published on June 23, is available here. The Wave revealed that organizations want real-time, consistent, connected, and trusted data to support their critical business operations and insights. However, new data sources, slow data movement between platforms, rigid data transformation workflows, and governance rules, expanding data volume, and distributed data across clouds and on-premises, can cause organizations to fail when executing

Founders launch Plural: a €250m fund for fellow ‘Unemployables’ building Europe’s next generation of tech companies28.6.2022 09:00:00 CEST | Press release

Plural, a new investment platform started by the founders and backers of Europe’s most significant tech companies, has unveiled today a €250m early stage venture fund (Plural Platform SCSp RAIF, “Plural”) to back the next generation of founders with global ambitions. Set up by Ian Hogarth, Khaled Heloui, Sten Tamkivi and Taavet Hinrikus - with other recognised founders who will announce themselves soon - Plural is a scalable investment platform whose investors are exclusively former founders and operators with decades of company building experience. Plural was founded because the Plural founders saw that across Europe the vast majority of investors lacked experience of building tech businesses. In Europe just 8% of investors are former operators, in contrast to more than half of tech investors in the US. Plural’s founders believe that the scar tissue from building tech companies is invaluable in helping the next generation of founders to build companies with global potential. Plural’s

Tele2 Estonia boosts performance with ADVA ALM fiber monitoring solution28.6.2022 09:00:00 CEST | Press release

ADVA (FSE: ADV) today announced that Tele2 Estonia has deployed the ADVA ALM fiber monitoring solution for real-time assurance across its national network. The compact, plug-and-play device boosts operational efficiency and service availability. This helps Tele2 Estonia to improve customer experience and offer enhanced SLAs. Managed by the Ensemble Controller network management system with Ensemble Fiber Director, the solution gives Tele2 Estonia’s field forces full control over their optical infrastructure. With its simple graphical overlay, the ADVA ALM precisely pinpoints the location of fiber impairments, enabling proactive maintenance, reducing repair times and preventing network outages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005471/en/ ADVA’s ALM is helping Tele2 Estonia to eliminate downtime and ensure services stay online. (Photo: Business Wire) “With the ADVA ALM, we can offer even more value to our c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom